Literature DB >> 7625817

New variant of TEM-10 beta-lactamase gene produced by a clinical isolate of proteus mirabilis.

T Palzkill1, K S Thomson, C C Sanders, E S Moland, W Huang, T W Milligan.   

Abstract

A clinical isolate of Proteus mirabilis was found to produce a new variant of the TEM-10 beta-lactamase gene. This is the first report of TEM-10 production by P. mirabilis and the first report of extended-spectrum beta-lactamase production by an isolate of this species recovered in the United States.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7625817      PMCID： PMC162712          DOI： 10.1128/AAC.39.5.1199

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Nucleotide sequences of CAZ-2, CAZ-6, and CAZ-7 beta-lactamase genes.

Authors:  C Chanal; M C Poupart; D Sirot; R Labia; J Sirot; R Cluzel
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

2.  A standard numbering scheme for the class A beta-lactamases.

Authors:  R P Ambler; A F Coulson; J M Frère; J M Ghuysen; B Joris; M Forsman; R C Levesque; G Tiraby; S G Waley
Journal:  Biochem J       Date:  1991-05-15       Impact factor: 3.857

3.  High-level resistance to cefotaxime and ceftazidime in Klebsiella pneumoniae isolates from Cleveland, Ohio.

Authors:  K S Thomson; C C Sanders; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

Review 4.  More extended-spectrum beta-lactamases.

Authors:  G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

5.  Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.

Authors:  V Jarlier; M H Nicolas; G Fournier; A Philippon
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

6.  Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBR322.

Authors:  J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

7.  Extended-spectrum beta-lactamase in Proteus mirabilis.

Authors:  S Mariotte; P Nordmann; M H Nicolas
Journal:  J Antimicrob Chemother       Date:  1994-05       Impact factor: 5.790

8.  In vitro and in vivo transferrable beta-lactam resistance due to a new plasmid-mediated oxyiminocephalosporinase from a clinical isolate of Proteus mirabilis.

Authors:  Y Watanabe; T Yokota; Y Higashi; Y Wakai; Y Mine
Journal:  Microbiol Immunol       Date:  1991       Impact factor: 1.955

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae.

Authors:  J P Quinn; D Miyashiro; D Sahm; R Flamm; K Bush
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191
View more
  16 in total

1.  Emerging extended-spectrum beta-lactamases in Proteus mirabilis.

Authors:  Laura Pagani; Roberta Migliavacca; Lucia Pallecchi; Cecilia Matti; Ernesto Giacobone; Gianfranco Amicosante; Egidio Romero; Gian Maria Rossolini
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

Review 2.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

3.  Comparison of screening methods for detection of extended-spectrum beta-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian teaching hospital.

Authors:  E Vercauteren; P Descheemaeker; M Ieven; C C Sanders; H Goossens
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

4.  Molecular characterization of a ceftazidime-resistant Morganella morganii isolate producing a TEM-10 beta-lactamase.

Authors:  H Barroso; A Freitas-Vieira; A Duarte
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

Review 5.  Catalytic properties of class A beta-lactamases: efficiency and diversity.

Authors:  A Matagne; J Lamotte-Brasseur; J M Frère
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

6.  TEM-187, a new extended-spectrum β-lactamase with weak activity in a Proteus mirabilis clinical strain.

Authors:  Stéphane Corvec; Racha Beyrouthy; Lise Crémet; Guillaume Ghislain Aubin; Frédéric Robin; Richard Bonnet; Alain Reynaud
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

7.  Chromosomally encoded ampC-type beta-lactamase in a clinical isolate of Proteus mirabilis.

Authors:  L Bret; C Chanal-Claris; D Sirot; E B Chaibi; R Labia; J Sirot
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

8.  Diversity of TEM mutants in Proteus mirabilis.

Authors:  R Bonnet; C De Champs; D Sirot; C Chanal; R Labia; J Sirot
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

9.  beta-Lactamases responsible for resistance to expanded-spectrum cephalosporins in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis isolates recovered in South Africa.

Authors:  J D Pitout; K S Thomson; N D Hanson; A F Ehrhardt; E S Moland; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Molecular characterization of a TEM-21 beta-lactamase in a clinical isolate of Morganella morganii.

Authors:  F Tessier; C Arpin; A Allery; C Quentin
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.